Amlodipine
Amlodipine(中文:氨氯地平) is a dihydropyridine calcium-channel blocker. It is used in the management of hypertension and angina.
Pronunciation
Amlodipine 10mg
Amlodipine 5mg
| HA Code: | |
|---|---|
| Generic Name: | Amlodipine |
| Brand Name: | NORVASC |
| Class: | Cardiovascular Drug |
| Subclass: | Calcium-channel Blocker, CCB |
| Legal Classification: | P1S1S3 |
Drug Names
| Generic Name 藥物化學名稱 | HA Code 藥物代碼 | Legal Classification法律藥物分類 | Brand Name 品牌名稱 |
|---|---|---|---|
| Amlodipine Besylate Tablet 5mg | AMLO01 | P1S1S3 | NORVASC |
| Amlodipine Besylate Tablet 10mg | AMLO02 | P1S1S3 | NORVASC |
Mechanism of Action
Amlodipine relaxes and widens blood vessels. It does this by blocking calcium going into muscles in the heart and blood vessels. Muscles need calcium to contract, so when you block the calcium, it makes the muscle cells relax. This lowers your blood pressure and makes it easier for your heart to pump blood around your body. In angina, amlodipine works by improving the blood and oxygen supply to your heart. Angina is chest pain that comes on when not enough blood gets to the muscles of the heart. This usually happens because the arteries going to the heart become hardened and narrowed.
Route of Administration
Amlodipine is given orally as the besylate, but doses are expressed in terms of the base. Amlodipine besylate 6.9 mg is equivalent to about 5 mg of amlodipine.
Dosage
Agina
- BY MOUTH
- Adult: initially 5 mg once daily; maximum 10 mg per day
Hypertension
- BY MOUTH
- Adult: initially 5 mg once daily; maximum 10 mg per day
Elderly
Amlodipine used at similar doses in elderly or younger patients.
Hepatic impairment
May need dose reduction – half-life prolonged
Side Effects
| System Organ Class | Frequency | Adverse reactions |
|---|---|---|
| Nervous system disorder | Common | Dizziness, headache (especially at the beginning of the treatment) |
| Eye disorders | Common | Visual disturbance (including diplopia) |
| Cardiac disorders | Common | palpitations |
| Uncommon | Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation) | |
| Vascular disorders | Common | flushing |
| Respiratory disorders | Common | dyspnoea |
| Gastro-intestinal disorders | Common | Abdominal pain, nausea, dyspepsia, altered bowel habits (including diarrhoea and constipation) |
| Very rare | Gingival hyperplasia | |
| Musculoskeletal and connective tissue disorders | Common | Ankle swelling, muscle cramps |
| General disorders | Common | Oedema, fatigue, asthemia |
Pharmacokinetics
After an oral dose, peak blood concentrations occur after 6 to 12 hours. | |- The bioavailability varies but is usually about 60 to 65%. | |- Amlodipine is reported to be about 98% bound to plasma proteins. It has a prolonged terminal elimination half-life of 35 to 50 hours and steady-state plasma concentrations are not achieved until after 7 to 8 days of use. | |- Amlodipine is extensively metabolized in the liver; metabolites are mostly excreted in urine, with less than 10% of a dose as unchanged drug. | |- How long does amlodipine take to work? Amlodipine starts to work on the day you start taking it, but it may be a couple of weeks before it takes full effect.
| Oral bioavailability | Bromazepam is well absorbed after oral doses. |
|---|---|
| Onset of action | Bromazepam is well absorbed after oral doses.
Peak plasma concentrations are reached between 0.5 and 4 hours of a dose. |
| Metabolism | Bromazepam is metabolized in the liver |
| Elimination half-life | Bromazepam is eliminated in the urine.
It has an elimination half-life of about 17 hours (range 11 – 22 hours). |
